CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--LumaCyte Corporation, a bioanalytical instrumentation leader in advanced label-free single-cell analytics, announced the successful completion of an A round financing that will allow the company to accelerate its global expansion efforts and service the increasing global demand of its flagship product, Radiance®. LumaCyte will also use these funds to further expand the company’s R&D efforts with a strong focus on bioproduction automation. In addition, LumaCyte announced the appointment of two industry executives, Paul M. Meister, and Peter L. Buzy, to its Board of Directors. “We are thrilled to welcome both Paul and Pete to LumaCyte’s board and know that their vast industry expertise across bioanalytical tools and cell and gene therapy (CGT) will bring incredible value and insights to our organization," says Sean J. Hart, LumaCyte CEO and CSO.
Paul Meister, a life science industry tools and investment veteran, brings decades of excellence in scaling scientific businesses into top tier global enterprises. Mr. Meister is a partner in Novalis LifeSciences, an investment and advisory firm for the life science industry as well as founder of Liberty Lane Partners, a private investment firm. Mr. Meister was at Thermo Fisher Scientific and Fisher Scientific for over 16 years; ultimately, becoming Chairman of the board. Mr. Meister currently serves on the Board of Directors of Ori Biotech, Quanterix and other private life science companies, and is Chairman of the board at Amneal Pharmaceuticals and Arbor Biotechnologies. "Paul's extensive business experience combined with his intimate knowledge of the analytical tools market will be an incredible asset to our team as we tackle the growing global demand for Radiance® and Laser Force Cytology ™(LFC) in the vaccine and CGT production sectors," says Renee Hart, LumaCyte President and CBO. "I am excited to join LumaCyte's board, having been an early investor and advisor to the company; I am incredibly impressed with the significant advancements the Radiance® platform brings to time sensitive and highly complex assays used in bioproduction. Having the ability to optimize processes in near real-time is game changing,” says Meister.
Pete Buzy, a seasoned life science executive in the cell and gene therapy space, brings a robust business and operations skill set from both private and public companies to LumaCyte’s board. Pete most recently served as Chairman of Catalent’s Gene Therapy division after joining the organization in 2019 where he was President of the Catalent Gene Therapy business unit after the acquisition of Paragon Bioservices, where Mr. Buzy held the titles of President & CEO. “LumaCyte’s Laser Force Cytology™ platform is driving significant value for biopharma, CDMOs and patients alike. New technologies that can deliver real-time cellular insights are vital in understanding changes throughout a bioprocess. I am thrilled to be part of such an innovative solution that has the ability to reduce production timelines, improve assay variability, and increase production yields. LumaCyte’s LFC analytics is opening the door to the future of science, and I can’t wait to see what this outstanding technology does in the CGT space,” says Buzy.
About LumaCyte
LumaCyte, Inc. is an advanced research and bioanalytics instrumentation company that produces label-free, single cell analysis and sorting instrumentation where the use of antibody or genetic labeling is not required for cellular analysis. This revolutionary technology utilizes Laser Force Cytology™ (LFC™) to measure optical and fluidic forces within a microfluidic channel to identify and measure the intrinsic cellular properties of each cell. The multivariate nature of the data has enabled a host of Big Data strategies and cloud computing capabilities that drive advanced analytics, allowing a deeper understanding of cell based biological systems. Applications of LumaCyte's label-free platform technology include viral infectivity for vaccine development and manufacturing, cell and gene therapy development and production monitoring, cancer biology R&D, CAR T-cell immunotherapy, adventitious agent testing (AAT), iPSCs, infectious disease, and pre-clinical drug discovery, in addition to multiple applications across the biomanufacturing sector for quality control and process optimization.
Innovate. Discover. Transform. ™
